精神心理科

订阅

MedSci主页 / 所有栏目 / 精神心理科

加拿大卫生部批准大冢和灵北的REXULTI（brexpiprazole）作为重度抑郁症的辅助疗法

2019-02-24 不详 网络

brexpiprazole加拿大卫生部重度抑郁症
关注

Otsuka Pharmaceutical Canada Inc.（大冢制药加拿大公司）和Lundbeck Canada Inc.（灵北制药加拿大公司）近日宣布，加拿大卫生部发布了对REXULTI（brexpiprazole）合规通知，将其作为抗抑郁的辅助药物，用于治疗对先前抗抑郁治疗反应不足的成人重度抑郁症（MDD）患者。

Otsuka Pharmaceutical Canada Inc.（大冢制药加拿大公司）和Lundbeck Canada Inc.（灵北制药加拿大公司）近日宣布，加拿大卫生部发布了对REXULTI（brexpiprazole）合规通知，将其作为抗抑郁的辅助药物，用于治疗对先前抗抑郁治疗反应不足的成人重度抑郁症（MDD）患者。Diane McIntosh博士说：“Brexpiprazole是MDD患者需要增强治疗的新选择。其独特的作用机制和潜在的益处将成为抗抑郁症的新途径”。

加拿大情绪障碍协会（MDSC）全国执行董事Dave Gallson说：“MDSC欢迎加拿大卫生部最近批准REXULTI（brexpiprazole）用于重症抑郁症（MDD）辅助治疗的决定。对于许多患有抑郁症且无法达到缓解标准的患者，这种创新治疗方法能够为患者及其家人带来希望。在最近的一项研究中，超过4％的加拿大人符合严重抑郁发作的标准，并且需要采用新的疗法来解决这一至关重要的问题”。


原始出处：

http://www.firstwordpharma.com/node/1626546#axzz5gKHwd300

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1714820, encodeId=a7fa1e14820fc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Sep 14 11:49:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771538, encodeId=e8481e7153847, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Wed Oct 02 03:49:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793327, encodeId=02401e93327cf, content=<a href='/topic/show?id=468715408bf' target=_blank style='color:#2F92EE;'>#Rexulti#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15408, encryptionId=468715408bf, topicName=Rexulti)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Nov 15 12:49:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650595, encodeId=3ae8165059521, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Mon Aug 12 22:49:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312601, encodeId=a950131260124, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443342, encodeId=f28d14433423a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-09-14 12498e5fm22(暂无昵称)

    #AZ#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1714820, encodeId=a7fa1e14820fc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Sep 14 11:49:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771538, encodeId=e8481e7153847, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Wed Oct 02 03:49:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793327, encodeId=02401e93327cf, content=<a href='/topic/show?id=468715408bf' target=_blank style='color:#2F92EE;'>#Rexulti#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15408, encryptionId=468715408bf, topicName=Rexulti)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Nov 15 12:49:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650595, encodeId=3ae8165059521, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Mon Aug 12 22:49:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312601, encodeId=a950131260124, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443342, encodeId=f28d14433423a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-10-02 rebeccajiejie

    #加拿大卫生部#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1714820, encodeId=a7fa1e14820fc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Sep 14 11:49:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771538, encodeId=e8481e7153847, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Wed Oct 02 03:49:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793327, encodeId=02401e93327cf, content=<a href='/topic/show?id=468715408bf' target=_blank style='color:#2F92EE;'>#Rexulti#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15408, encryptionId=468715408bf, topicName=Rexulti)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Nov 15 12:49:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650595, encodeId=3ae8165059521, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Mon Aug 12 22:49:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312601, encodeId=a950131260124, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443342, encodeId=f28d14433423a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-11-15 12498c32m68暂无昵称

    #Rexulti#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1714820, encodeId=a7fa1e14820fc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Sep 14 11:49:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771538, encodeId=e8481e7153847, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Wed Oct 02 03:49:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793327, encodeId=02401e93327cf, content=<a href='/topic/show?id=468715408bf' target=_blank style='color:#2F92EE;'>#Rexulti#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15408, encryptionId=468715408bf, topicName=Rexulti)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Nov 15 12:49:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650595, encodeId=3ae8165059521, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Mon Aug 12 22:49:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312601, encodeId=a950131260124, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443342, encodeId=f28d14433423a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-08-12 sodoo

    #辅助疗法#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1714820, encodeId=a7fa1e14820fc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Sep 14 11:49:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771538, encodeId=e8481e7153847, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Wed Oct 02 03:49:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793327, encodeId=02401e93327cf, content=<a href='/topic/show?id=468715408bf' target=_blank style='color:#2F92EE;'>#Rexulti#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15408, encryptionId=468715408bf, topicName=Rexulti)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Nov 15 12:49:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650595, encodeId=3ae8165059521, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Mon Aug 12 22:49:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312601, encodeId=a950131260124, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443342, encodeId=f28d14433423a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-02-26 shanyongle

    #加拿大#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1714820, encodeId=a7fa1e14820fc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Sep 14 11:49:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771538, encodeId=e8481e7153847, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Wed Oct 02 03:49:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793327, encodeId=02401e93327cf, content=<a href='/topic/show?id=468715408bf' target=_blank style='color:#2F92EE;'>#Rexulti#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15408, encryptionId=468715408bf, topicName=Rexulti)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Nov 15 12:49:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650595, encodeId=3ae8165059521, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Mon Aug 12 22:49:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312601, encodeId=a950131260124, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443342, encodeId=f28d14433423a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Tue Feb 26 07:49:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-02-26 12498e67m29暂无昵称

    #卫生部#

    0

相关资讯

加拿大卫生部批准Otsuka/Lundbeck公司的REXULTI（brexpiprazole）用于重度抑郁症的辅助治疗

Otsuka和Lundbeck公司宣布，加拿大卫生部批准REXULTI（brexpiprazole）作为辅助抗抑郁药，用于对当前发作期间的现有抗抑郁治疗反应差的重度抑郁症（MDD）成人患者。

灵北和大冢重磅精神病药物Rexulti获美国FDA批准用于精神分裂症的维持治疗

丹麦药企灵北（H.Lundbeck）和日本药企大冢（Otsuka）近日联合宣布，美国食品和药物管理局（FDA）已批准扩大精神病新药Rexulti（brexpiprazole）的药物标签，用于精神分裂症成人患者的维持治疗。 Rexulti是一种每日一次的口服药物，由大冢发现，由灵北和大冢联合开发，该药于2015年7月获FDA批准Rexulti：（1）作为一种辅助药物用于重度抑郁症（MDD）成人

神分裂症新药进展！灵北和大冢在日本提交重磅精神分裂症药物Rexulti上市申请

日本药企大冢（Otsuka）近日宣布，已向日本劳动卫生福利部（MHLW）提交了精神病药物Rexulti（brexpiprazole）的新药申请（NDA），该NDA寻求批准Rexulti在日本上市销售，用于精神分裂症（schizophrenia）成人患者的治疗。Rexulti是一种每日一次的口服药物，由大冢发现，由大冢与丹麦药企灵北（H.Lundbeck）合作全球开发。在美国，Rexulti于